Patients with MDD were randomly assigned in a 1:1:1 ratio to receive 1.5 mg daily cariprazine, 3.0 mg daily cariprazine, or placebo for 6 weeks.
Your search for major depressive disorder returned 31 results
Click on a filter below to refine your search. Remove a filter to broaden your search.
Investigators designed this study to evaluate the feasibility and potential utility of a peer-led CBT-based workshop for PPD.
Inpatients with schizophrenia spectrum disorders were randomly assigned to receive treatment as usual with or without a yoga-based group intervention for 4 weeks.
Patients who had treatment-naïve MDD were recruited in the US between 2007 and 2013 for the Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) study.
Investigators searched publication databases for randomized controlled trials evaluating cognitive training and remediation interventions among patients with MDD.
The Alpha-Stim-D trial was a noncommercial, multicenter, randomly assigned, parallel group, double-blind trial conducted at 25 primary care practices in the United Kingdom.
The REAL-ESK study was an observational, retrospective, multicenter study conducted in Italy.
Investigators sourced data for this study from the Stockholm Major Depressive Disorder Cohort. Between 2010 and 2018, all patients in the Stockholm region who met the criteria for MDD were enrolled in the cohort.
Can reducing RNT with psychological treatment approaches help improve youth depression and anxiety?
Investigators looked into which treatment fared better for patients with anxiety disorders: a mindfulness-based stress reduction intervention or escitalopram.
Researchers assessed characteristics and correlates of metabolic syndrome in adolescents with major depressive disorder or bipolar disorder depression.
Researchers compared the white matter networks of patients with remitted major depressive disorder and remitted bipolar disorder to find disease-specific alterations.
Researchers evaluated the efficacy of dextromorphan-bupropion among patients with major depressive disorder and comorbid anxiety.
Researchers investigated whether individuals with symptoms of depression were more sensitive to missed opportunities.
Researchers searched for protective effects in gut microbiota from the pathogenesis of major depressive disorder.
A cross-sectional family study sought to determine if parents’ transmission of anxiety is sex specific.
The researchers sought to examine whether inflammation and white matter microstructure play a role in treatment response in major depressive disorder.
Outpatients were recruited at the Instituto Nacional de Psiquiatía (National Institute of Psychiatry) in Mexico and were evaluated for alcohol dependence and major depressive disorder.
For this study, community-dwelling adults were evaluated for major depressive disorder, generalized anxiety disorder, and global sleep quality over an 18 year period.
Inpatients with persistent depressive disorder were recruited at a German University Hospital for a 10-week inpatient treatment with the Cognitive Behavioral Analysis System of Psychotherapy.
This observational study was conducted by telephone interviews between April and July 2020.
Patients with somatoform disorders, major depressive disorder, and healthy controls were recruited between 2016 and 2017 at the Ambulante Psychosoziale Rehabilitation in Austria and Schoen Clinic Roseneck in Germany.
For this study, patients with generalized anxiety disorder were recruited from the Nanfang Hospital in China between 2018 and 2020.
This prospective, multi-center, open-label trial, CAN-BIND-1 was conducted between 2012 and 2017.
Previous studies have found that perinatal women have had detriments to sleep and depression during the pandemic; however, all studies to date in the perinatal setting have lacked a comparator group, so robust conclusions about the effect of the COVID-19 pandemic have not been elucidated.
Data for this study were sourced from 4 active treatment arms of 4 randomized, controlled trials conducted by the National Institutes of Health in the United States between 2006 and 2018.
Patients with treatment-resistant major depressive disorder or bipolar disorder without psychotic symptoms received intravenous infusions of 0.5 mg/kg ketamine 3 times per week for 2 weeks.
This retrospective cohort study evaluated patient data from patients aged 50 years or older who received an acute course of ECT between 2011 and 2019 and were evaluated for cognition and depression outcomes on the basis of baseline cognitive function.
Major depressive episodes reduce visual contrast suppression among patients with depressive disorders, a study shows.
Psilocybin has been shown to have antidepressant properties. With direct comparisons between psilocybin and established treatments for depression lacking, the study researchers looked at psilocybin and escitalopram.
Latest News Your top articles for SundayFor More Personalized News
Haymarket Medical NetworkTop Picks
Continuing Medical Education (CME/CE) Courses